Who Paid My Doc
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women
ClinicalTrials.gov NCT03271489
Research payments
$1,826,838
Through program year 2021, $1,826,838 in research payments was reported against A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women, across 985 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT03271489
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $1,826,838 | 985 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Liesl Smith Dallas, TX Named on 54 payments
- James Cain Lampasas, TX Named on 30 payments
- Alyssa Kratochvil Fall River, MA Named on 26 payments
- Jennefer Sutton Shavano Park, TX Named on 25 payments
- Jin Hee Kim New York, NY Named on 24 payments
- Pamela Moore Plano, TX Named on 22 payments
- Awoniyi Awonuga Southfield, MI Named on 22 payments
- Ramin Farsad Encinitas, CA Named on 20 payments
- Parke Hedges San Antonio, TX Named on 20 payments
- Bryan Feldman Columbus, OH Named on 20 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.